Look at how NeedleBay evolved through significant trials at Cardiff University and analysis by the University of Reading.
Evolution of the NeedleBay
NeedleBay system has come a long way in its design and specification, driven by thorough trials and insightful research. This journey, marked by innovation and a user-focused approach, promises to transform diabetes management. Let’s look back at how NeedleBay has evolved since its original development, including significant trials at Cardiff University and analysis by the University of Reading, leading up to its relaunch in 2004.
Addressing Medication Adherence Challenges
A comprehensive trial at Cardiff University School of Healthcare Sciences, involved over 250 participants testing a specially adapted version of NeedleBay. This trial aimed to improve the management of insulin pen needles and ensure accurate insulin usage over time. Given the staggering £3 billion annual diabetes-related healthcare costs in the UK, improving medication compliance is crucial.
The Cardiff study targeted challenges in adhering to medication regimens, with non-compliance leading to severe health complications and increased healthcare costs. NeedleBay’s trial version simplified insulin pen needle management, helping patients maintain their medication schedules.
Insights from the University of Reading
The University of Reading analysed the trial data, providing insights into NeedleBay’s efficacy. The findings, significant enough to be presented at the European Association for the Study of Diabetes (EASD) meeting in Stockholm, confirmed NeedleBay’s potential to reduce non-compliance. The data showed marked improvements in participants’ management of their insulin regimens, suggesting better health outcomes and reduced long-term healthcare costs.
Launch of the New NeedleBay System.
Based on positive results from the Cardiff trial and the University of Reading’s analysis, NeedleBay has developed a new version of its system, which will be launched in 20024. This version, featuring four pen needle bays, incorporates feedback and findings from the trial, promising up to an 88% improvement in self-management of diabetes medication. Initially available in the UK and the USA, the new NeedleBay device represents a significant milestone, offering a meticulously tested and refined solution to meet the needs of diabetes patients.
Why not get in touch with us and find out more about our NeedleBay products. Or order one today to see the benefits for yourself.
